Subscribe
shutterstock_1562870302_elnur
Elnur / Shutterstock.com
15 February 2021Big PharmaAlex Baldwin

LSPN Connect: Monetising your IP portfolio

Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Connect: The battle for COVID-19 vaccines
22 June 2021   With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.
Biotechnology
LSPN LIVE 2021: an ‘unmissable opportunity’
28 September 2021   Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.
Americas
LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty
7 October 2021   The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
LSPN Connect: The battle for COVID-19 vaccines
22 June 2021   With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.
Biotechnology
LSPN LIVE 2021: an ‘unmissable opportunity’
28 September 2021   Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.
Americas
LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty
7 October 2021   The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

More on this story

Big Pharma
LSPN Connect: The battle for COVID-19 vaccines
22 June 2021   With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.
Biotechnology
LSPN LIVE 2021: an ‘unmissable opportunity’
28 September 2021   Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.
Americas
LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty
7 October 2021   The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York